Andere talen Sangamo Therapeutics, Inc.

Aandelen

SGMO

US8006771062

Geschatte realtime Cboe BZX Andere beurzen 21:30:51 07-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,579 ^USD	-2,15%		+1,61%	+5,56%

14/05	Transcript : Sangamo Therapeutics, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 08:30 AM
09/05	Transcript : Sangamo Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Sangamo: Q1 Earnings Snapshot	09/05
Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000	09/05
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results	09/05
Sangamo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024	09/05
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing	09/05
Sangamo Therapeutics : ASGCT 2024	09/05
Sangamo Therapeutics : Site-directed integration of large DNA sequences into endogenous sites in the human genome using engineered Modular Integrases (MINTS)	08/05
Sangamo Therapeutics : Widespread CNS Tau Knockdown for the Potential Treatment of Alzheimer’s Disease and other Tauopathies	08/05
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast	02/05
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data from Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting	23/04
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)	22/04
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering	25/03
Sangamo Therapeutics Prices $24 Million Registered Direct Offering	22/03
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering	22/03
Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	14/03
Sangamo: Q4 Earnings Snapshot	13/03
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	13/03
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs	13/03
Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023	13/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Sangamo Therapeutics, Inc.

Aandelen

SGMO

US8006771062

Andere talen

Filters